World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Best Female Scientists

D-Index
126
Citations
87730
World Ranking
409
National Ranking
18

Medicine

D-Index
135
Citations
100584
World Ranking
2018
National Ranking
98

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2025 - Research.com Best Female Scientists Award

Overview

Sibylle Loibl is affiliated with Goethe University Frankfurt in Germany. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a substantial focus on Oncology and Cancer Research. Additional areas of sub-specialization include Pulmonary and Respiratory Medicine, Genetics, and Molecular Biology.

The scientist's work covers several major topics related to cancer, including:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Breast Lesions and Carcinomas
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Sibylle Loibl has contributed extensively to the academic literature, with recent notable papers including:

  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020, The Lancet)
  • "Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer" (2021, New England Journal of Medicine)
  • "Breast cancer" (2021, The Lancet)
  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021, New England Journal of Medicine)
  • "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer" (2021, Annals of Oncology)

The scientist's research has frequently been published in several high-profile journals, including:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • European Journal of Cancer

Collaboration has been a significant aspect of Sibylle Loibl's work, with frequent co-authors including:

  • Carsten Denkert
  • Michael Untch
  • Peter A. Fasching
  • Valentina Nekljudova
  • Andreas Schneeweiß

The breadth of publications and co-authorships indicates active engagement in multi-disciplinary cancer research, placing particular emphasis on breast cancer therapies, molecular and genetic mechanisms of cancer, and clinical applications in oncology.

Best Publications

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

    Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • HER2-positive breast cancer

    Sibylle Loibl;Luca Gianni

Frequent Co-Authors

Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Jens Huober
Jens Huober Kantonsspital St. Gallen
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Volkmar Müller
Volkmar Müller Universität Hamburg
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine or healthcare but are looking for flexible learning options, online degrees can provide valuable career openings. With healthcare evolving rapidly, many students now pursue specialized programs and leadership roles through accredited online options.

For those interested in mental health, psych np online programs offer a pathway to becoming a psychiatric nurse practitioner. These programs deliver focused training that can lead to rewarding careers in behavioral health.

Many graduates also consider administrative roles in healthcare. Options like the cheapest mha programs online and affordable mha online degrees can prepare students for management and leadership positions, often at a lower cost and with increased flexibility.

Nurses aiming for the highest clinical practice level may explore the best online bsn to dnp programs. These advanced degrees support a significant step up in expertise, opening doors to more autonomous clinical roles.

Best Scientists Citing Sibylle Loibl

Trending Scientists